



To date, there has been no reliable way to detect early onset preeclampsia, particularly for patients experiencing their first pregnancy. Therefore, there has been no satisfactory method with which to stratify patients at high risk of early onset preeclampsia from those at lower risk. **Until now.**

PreeclampsiaScreenSM | T1

The Power to Know Sooner

PreeclampsiaScreenSM | T1 enables accurate detection of early onset preeclampsia risk, by analyzing three biochemical markers in the mother's serum: **PAPP-A**, **PIGF** and **AFP** in combination with **mean arterial pressure** and **uterine artery Doppler pulsatility index**, to achieve up to a **91% detection rate** (5% FPR). Early detection of early onset preeclampsia allows a valuable window of opportunity for vigilance and intervention, including the use of low-dose aspirin.

EOPE occurs in as many as 1 in 200 pregnancies and is defined as delivery <34 weeks gestation.^{1,2}

Preeclampsia contributes to 70,000 maternal deaths,³ and 500,000 fetal/newborn deaths each year.^{4,5} Mortality and morbidity rates continue to rise.³

More than 55% of all EOPE occurs in nulliparous women.^{6,7}

Preeclampsia and other hypertensive disorders of pregnancy are still a leading cause of maternal and infant death and have severe health consequences.

Did you know? ACOG and the Preeclampsia Foundation recently endorsed bipartisan legislation to strengthen state efforts to prevent maternal deaths. The Preventing Maternal Deaths Act will support states in establishing or expanding their mortality review efforts.

[READ MORE](#)

ASPRE Update

The ASPRE Project is a large, international, prospective trial examining the prophylactic use of low-dose aspirin beginning in the first trimester of pregnancy in women that screen high risk for preeclampsia. The ASPRE study is now completed and the data analysis is under way.

READ MORE

For more information about the PreeclampsiaScreenSM | T1 test, visit us online at ntd-eurofins.com/preeclampsia, or call us at 1-888-NTD-LABS (683-5227).

Make sure to visit NTD at booth #1119 during ACOG's annual conference May 7 – 8th in San Diego, CA, to learn more about early onset preeclampsia and how screening can help you improve clinical focus.

About Eurofins NTD

For more than 30 years, Eurofins NTD has pioneered the research and development of prenatal screening protocols for open neural tube defects, Down syndrome, trisomy 13 and 18, and early onset preeclampsia screening. Today, Eurofins NTD serves universities, medical centers, hospitals, laboratories, obstetricians and maternal fetal medicine specialists worldwide, providing risk assessment services that help health care professionals and patients make more informed medical decisions.

References

1. Espinoza J, Romero R, Nien JK, et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. *Am J Obstet Gynecol.* 2007;196(4): 326, e1-12.
2. Espinoza J, Kusanovic JP, Bahado-Singh R, et al. Should bilateral uterine artery notching be used in the risk assessment for preeclampsia, small-for-gestational-age, and gestational hypertension? *J Ultrasound Med.* 2010;29(7):1103-1115.
3. AbouZhar C. Global burden of maternal death and disability. *Br Med Bull.* 2003;67: 1-11.
4. Anderson UD, Olsson MG, Kristensen KH, Akerstrom B, Hansson SR. Review: Biochemical markers to predict preeclampsia. *Placenta.* 2012;33. Suppl S42-7.
5. Preeclampsia Foundation. Preeclampsia and maternal mortality: a global burden. 1 May 2013. Available at <https://www.preeclampsia.org/health-information/149-advocacy-awareness/332-preeclampsia-and-maternal-mortality-a-global-burden>. Accessed May 4, 2017.
6. Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. *Am J Obstet Gynecol.* 2013;209(6):544.e1-544.e12.
7. Park F, Russo K, Williams P, et al. Prediction and prevention of early onset pre-eclampsia: The impact of aspirin after first-trimester screening. *Ultrasound Obstet Gynecol.* 2015;46(4): 419-423.

©2017 Eurofins NTD, LLC. All Rights Reserved.